QQ客服 官方微博 反馈留言

浏览/检索结果: 共21条，第1-10条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer 期刊论文 2019, 卷号: 30, 期号: 4, 页码: 558-566 作者:  Robson, M. E.;  Tung, N.;  Conte, P.;  Im, S-A;  Senkus, E. 收藏  |  浏览/下载：8/0  |  提交时间：2020/01/03 breast cancer  germline BRCA mutation  overall survival  PARP inhibitor  olaparib  tolerability   Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 会议论文 作者:  Senkus-Konefka, E.;  Domchek, S. M.;  Im, S. A.;  Xu, B.;  Armstrong, A. 收藏  |  浏览/下载：12/0  |  提交时间：2019/12/05 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) 期刊论文 2018, 卷号: 29, 期号: 8, 页码: 1634-1657 作者:  Cardoso, F.;  Senkus, E.;  Costa, A.;  Papadopoulos, E.;  Aapro, M. 收藏  |  浏览/下载：8/0  |  提交时间：2020/01/03 breast cancer  metastatic  advanced  guidelines  ABC  ESO-ESMO   Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 会议论文 EUROPEAN JOURNAL OF CANCER, 2018-04-01 作者:  Senkus-Konefka, E.;  Domchek, S. M.;  Im, S. A.;  Xu, B.;  Armstrong, A. 收藏  |  浏览/下载：16/0  |  提交时间：2020/01/03 Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 期刊论文 2018, 卷号: 92, 页码: S19-S20 作者:  Senkus-Konefka, E.;  Domchek, S. M.;  Im, S. A.;  Xu, B.;  Armstrong, A. 收藏  |  浏览/下载：8/0  |  提交时间：2020/01/03 OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) 期刊论文 2018, 卷号: 78, 期号: 13 作者:  Robson, Mark E.;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe;  Domchek, Susan 收藏  |  浏览/下载：10/0  |  提交时间：2020/01/03 OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) 会议论文 CANCER RESEARCH, 2018-07-01 作者:  Robson, Mark E.;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe;  Domchek, Susan 收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03 OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) 期刊论文 Journal of Clinical Oncology, 2017, 卷号: 35 作者:  Robson M.E., Im S.-A., Senkus E., Xu B., Domchek S.M., Masuda N., Delaloge S., Li W., Tung N.M., Armstrong A., Wu W., Goessl C.D., Runswick S., Conte P.F. 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05 OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). 会议论文 作者:  Robson, Mark E.;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe;  Domchek, Susan M. 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/05 OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician"s choice 会议论文 作者:  Runswick, S.;  Robson, M.;  Conte, P. F.;  Im, S-A.;  Senkus-Konefka, E. 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05